McKesson stock in focus after higher fiscal 2027 EPS outlook
AI-generated analysis
Key insights
๐ McKesson reported fiscal second-quarter revenue growth of 8% year over year, reaching $111.0 billion for the quarter ended September 30.
๐ฐ Adjusted diluted earnings per share surged 18% to $11.68, while GAAP diluted earnings per share rose to $10.44 from $8.92.
๐ต The company generated $3.1 billion in operating cash flow and $2.9 billion in free cash flow during the quarter.
๐ Management raised fiscal 2027 adjusted earnings guidance to a range of $45.60 to $46.40 per diluted share.
๐ The new guidance implies adjusted earnings growth of 17% to 19%, surpassing the long-term target range of 13% to 16%.
๐ฅ Growth was driven by North American Pharmaceutical, Oncology, Multispecialty, and Prescription Technology Solutions segments.
๐ Lower contributions from branded pharmaceuticals partially offset gains but did not hinder overall revenue expansion.
๐ณ๐ด The updated outlook includes effects from the Norway divestiture and net gains within The US Oncology Network in fiscal 2026.
๐ฎ Management expects fiscal 2027 revenue growth of 6% to 10% and adjusted operating profit growth of 12% to 16%.
๐ McKesson stock traded at 982.40 euros on Lang & Schwarz as of November 12, 2026.
๐ Bullish signals
๐McKesson reported a significant 8% year-over-year increase in fiscal second-quarter revenue, reaching $111.0 billion.
๐ฐAdjusted diluted earnings per share rose 18% to $11.68, demonstrating strong profitability growth.
๐ตThe company generated substantial cash flow with $3.1 billion in operating cash flow and $2.9 billion in free cash flow.
๐Management raised fiscal 2027 adjusted earnings guidance to $45.60-$46.40, expanding the previous range of $44.20-$45.00.
๐The updated guidance implies adjusted earnings growth of 17% to 19%, exceeding the long-term target range of 13% to 16%.
๐ฅGrowth was supported by higher prescription volumes and strong performance in Oncology, Multispecialty, and Prescription Technology Solutions segments.
Article
McKesson reported robust fiscal second-quarter results, with consolidated revenue rising 8% year over year to $111.0 billion for the quarter ended September 30. Adjusted diluted earnings per share increased significantly by 18% to $11.68, while GAAP diluted earnings per share climbed to $10.44 from $8.92 in the prior year.
The healthcare distributor generated strong cash flow metrics, producing $3.1 billion in operating cash flow and $2.9 billion in free cash flow during the period. Management attributed this operational progress to growth within North American Pharmaceutical, Oncology, Multispecialty, and Prescription Technology Solutions segments, supported by higher prescription volumes and specialty-product distribution.
Following these results, McKesson raised its fiscal 2027 adjusted earnings per diluted share guidance to a range of $45.60 to $46.40, up from the previous range of $44.20 to $45.00. This updated outlook implies adjusted earnings growth of 17% to 19% compared with the prior year, exceeding the company's long-term target range of 13% to 16% when excluding specific divestiture and network gain effects.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
McKesson reported robust fiscal second-quarter results, with consolidated revenue rising 8% year over year to $111.0 billion for the quarter ended September 30. Adjusted diluted earnings per share increased significantly by 18% to $11.68, while GAAP diluted earnings per share climbed to $10.44 from $8.92 in the prior year.
The healthcare distributor generated strong cash flow metrics, producing $3.1 billion in operating cash flow and $2.9 billion in free cash flow during the period. Management attributed this operational progress to growth within North American Pharmaceutical, Oncology, Multispecialty, and Prescription Technology Solutions segments, supported by higher prescription volumes and specialty-product distribution.
Following these results, McKesson raised its fiscal 2027 adjusted earnings per diluted share guidance to a range of $45.60 to $46.40, up from the previous range of $44.20 to $45.00. This updated outlook implies adjusted earnings growth of 17% to 19% compared with the prior year, exceeding the company's long-term target range of 13% to 16% when excluding specific divestiture and network gain effects.
๐ Q2 revenue grew 8% YoY to $111.0 billion.
๐ฐ Adjusted EPS surged 18% to $11.68.
๐ต Operating cash flow reached $3.1 billion.
๐ Raised FY2027 adjusted earnings guidance to $45.60-$46.40.
๐ฎ Expects FY2027 revenue growth of 6% to 10%.
๐ McKesson reported fiscal second-quarter revenue growth of 8% year over year, reaching $111.0 billion for the quarter ended September 30.
๐ฐ Adjusted diluted earnings per share surged 18% to $11.68, while GAAP diluted earnings per share rose to $10.44 from $8.92.
๐ต The company generated $3.1 billion in operating cash flow and $2.9 billion in free cash flow during the quarter.
๐ Management raised fiscal 2027 adjusted earnings guidance to a range of $45.60 to $46.40 per diluted share.
๐ The new guidance implies adjusted earnings growth of 17% to 19%, surpassing the long-term target range of 13% to 16%.
๐ฅ Growth was driven by North American Pharmaceutical, Oncology, Multispecialty, and Prescription Technology Solutions segments.
๐ Lower contributions from branded pharmaceuticals partially offset gains but did not hinder overall revenue expansion.
๐ณ๐ด The updated outlook includes effects from the Norway divestiture and net gains within The US Oncology Network in fiscal 2026.
๐ฎ Management expects fiscal 2027 revenue growth of 6% to 10% and adjusted operating profit growth of 12% to 16%.
๐ McKesson stock traded at 982.40 euros on Lang & Schwarz as of November 12, 2026.
Bullish Signals
Revenue grew 8% YoY to $111.0B in Q2.
Adjusted EPS rose 18% to $11.68.
Operating cash flow reached $3.1 billion.
Raised FY2027 guidance to $45.60-$46.40.
Growth driven by higher prescription volumes.
Bullish Signals
McKesson reported a significant 8% year-over-year increase in fiscal second-quarter revenue, reaching $111.0 billion.
Adjusted diluted earnings per share rose 18% to $11.68, demonstrating strong profitability growth.
The company generated substantial cash flow with $3.1 billion in operating cash flow and $2.9 billion in free cash flow.
Management raised fiscal 2027 adjusted earnings guidance to $45.60-$46.40, expanding the previous range of $44.20-$45.00.
The updated guidance implies adjusted earnings growth of 17% to 19%, exceeding the long-term target range of 13% to 16%.
Growth was supported by higher prescription volumes and strong performance in Oncology, Multispecialty, and Prescription Technology Solutions segments.
McKesson Corporation (NYSE: MCK) has announced plans to spin off its Medical-Surgical Solutions segment into a separate, independent company. This strategic move involves the separation of a specific business unit from the larger healthcare distribution conglomerate.
As part of this restructuring initiative, Apollo-affiliated investors have committed to investing US$1.25 billion in the newly formed Medical-Surgical Solutions entity. This capital injection is intended to support the new company's operations and growth trajectory following the separation.
McKesson remains a major player in the US healthcare distribution industry with a total market capitalization of approximately US$122.5 billion. The spin-off represents a significant corporate action that could alter the company's future financial profile and operational focus.
๐ข McKesson plans to spin off its Medical-Surgical Solutions segment into an independent company.
๐ฐ Apollo-affiliated investors agreed to invest US$1.25 billion in the new entity.
๐ฅ McKesson is a large US healthcare distributor with a market cap of US$122.5 billion.
๐ The separation isolates Medical-Surgical Solutions from McKesson's broader operations.
๐ข McKesson plans to spin off its Medical-Surgical Solutions segment into a separate, independent company.
๐ฐ Apollo-affiliated investors have agreed to invest US$1.25 billion in the new Medical-Surgical Solutions entity.
๐ฅ McKesson is a large US healthcare distributor with a total market capitalization of approximately US$122.5 billion.
๐ The separation involves isolating the Medical-Surgical Solutions business from the parent corporation's broader operations.
Bullish Signals
Apollo investors commit US$1.25B to spun-off Medical-Surgical Solutions.
Spin-off enables focus on core distribution businesses.
Apollo-affiliated investors have committed to investing US$1.25 billion in the new Medical-Surgical Solutions entity, providing significant capital support for the spun-off business.
The spin-off allows McKesson to focus on its core distribution businesses while creating a standalone entity with dedicated funding.
Risk Factors
The separation of the Medical-Surgical Solutions segment represents a major structural change that may introduce integration complexities or operational adjustments for the remaining company.
McKesson reported robust fiscal second-quarter results, driving a notable increase in its stock price. Consolidated revenue surged by 8 percent year over year to reach $111.0 billion, while adjusted earnings per diluted share climbed 18 percent to $11.68. This strong performance was fueled by growth across key segments including North American Pharmaceutical, Oncology and Multispecialty, and Prescription Technology Solutions.
Following the quarterly update, management raised its full-year fiscal 2027 adjusted EPS guidance range from $44.20 to $45.00 to a new range of $45.60 to $46.40. This upward revision implies an expected growth rate of 17 percent to 19 percent for the full year, excluding specific divestiture impacts and prior gains from The US Oncology Network. Management projects fiscal 2027 revenue growth between 6 percent and 10 percent, with operating profit anticipated to rise by 12 percent to 16 percent.
Analyst sentiment remains positive following the earnings release. Morgan Stanley increased its price target for McKesson to $1,260 from $1,207 while maintaining an Overweight rating. The firm cited the quarterly update as a catalyst for the adjustment, providing investors with a fresh reference point for the second half of the fiscal year. North American Pharmaceutical remains a primary operating focus, with full-year operating profit growth projected between 14 percent and 18 percent.
๐ McKesson Q2 revenue grew 8% to $111.0 billion.
๐ฐ Adjusted EPS rose 18% year-over-year to $11.68.
๐ฆ Morgan Stanley raised price target to $1,260.
๐ McKesson reported fiscal Q2 revenue growth of 8% to $111.0 billion, driven by performance in North American Pharmaceutical, Oncology, and Prescription Technology Solutions.
๐ฐ Adjusted earnings per diluted share increased 18% year-over-year to $11.68, supported by strong operating momentum and a lower share count.
๐ Management raised fiscal 2027 adjusted EPS guidance to a range of $45.60 to $46.40, implying 17% to 19% growth from the prior fiscal year.
๐ The company forecasts fiscal 2027 revenue growth of 6% to 10% and operating profit growth of 12% to 16%, with North American Pharmaceutical projected for 14% to 18% profit growth.
๐ฆ Morgan Stanley raised its price target to $1,260 and maintained an Overweight rating following the strong quarterly results and guidance hike.
๐ Operating momentum and a lower share count were cited as key drivers supporting the significant increase in adjusted earnings per diluted share.
Bullish Signals
Revenue grew 8% to $111.0B in Q2.
Bullish Signals
McKesson reported fiscal Q2 revenue growth of 8% to $111.0 billion, driven by strong performance across North American Pharmaceutical, Oncology, and Prescription Technology Solutions.
Adjusted earnings per diluted share surged 18% year-over-year to $11.68, supported by robust operating momentum and a lower share count.
Management raised fiscal 2027 adjusted EPS guidance to a range of $45.60 to $46.40, implying 17% to 19% growth from the prior fiscal year.
The company forecasts fiscal 2027 revenue growth of 6% to 10% and operating profit growth of 12% to 16%, with North American Pharmaceutical projected for 14% to 18% profit growth.
Morgan Stanley raised its price target to $1,260 and maintained an Overweight rating following the strong quarterly results and guidance hike.
McKesson Corporation is preparing to release its fiscal second-quarter 2027 earnings report on Wednesday, November 4, following the market close. The pharmaceutical distributor enters this reporting period with a strong momentum from its first quarter, having previously exceeded Wall Street's earnings per share (EPS) estimates in each of its last four quarterly reports.
Analysts project that McKesson will report diluted EPS of $10.69 for the quarter, representing an 8.4% increase compared to the same period a year ago. Management has set a specific target range for adjusted fiscal 2027 earnings per share between $44.20 and $45.00, which investors will scrutinize alongside the company's full-year guidance.
The upcoming results are critical as they serve as the next major catalyst for McKesson's investment case. Market participants are closely watching whether the company can sustain its recent profit growth trajectory and if management adjusts its outlook based on the quarterly performance. The stock recently traded at 885.00 euros, reflecting investor anticipation of the earnings release.
McKesson's first quarter provided a solid operating benchmark with revenue of $105.4 billion and adjusted EPS of $9.93, both surpassing analyst expectations. This consistent outperformance has raised the bar for the November update, where any deviation from consensus could significantly impact the company's valuation and longer-term guidance narrative.
๐ McKesson reports Q2 2027 results after market close Nov 4.
๐ฐ Analysts expect EPS to rise 8.4% to $10.69.
๐ฏ Management targets adjusted FY2027 EPS between $44.20-$45.00.
๐ McKesson has beaten EPS estimates for four consecutive quarters.
๐ Investors assess if earnings momentum continues into fiscal year 2027.
๐ McKesson is scheduled to report fiscal second-quarter 2027 results after the market close on Wednesday, November 4.
๐ฐ Analysts expect quarterly diluted earnings per share to rise to $10.69, up 8.4% from the year-earlier period of $9.86.
๐ฏ Management targets adjusted fiscal 2027 earnings per share in the range of $44.20 to $45.00.
๐ McKesson has exceeded Wall Street's EPS estimates in each of its last four quarterly reports.
๐ต The company reported first-quarter revenue of $105.4 billion and adjusted EPS of $9.93, beating analyst estimates.
๐ Investors are assessing whether recent earnings momentum can continue into the second half of the fiscal year.
๐ A result above consensus could reinforce the earnings narrative, while a weaker outlook could impact longer-term guidance.
๐ข The pharmaceutical distributor is focusing on the development of its core business during this reporting period.
Bullish Signals
Beat EPS estimates for four consecutive quarters.
Q1 revenue hit $105.4B with adjusted EPS of $9.93.
Analysts forecast 8.4% YoY EPS growth to $10.69.
Management targets $44.20-$45.00 adjusted EPS for fiscal 2027.
Bullish Signals
McKesson has exceeded Wall Street's EPS estimates in each of its last four quarterly reports, demonstrating consistent outperformance.
The company reported first-quarter revenue of $105.4 billion and adjusted EPS of $9.93, both surpassing cited Wall Street estimates.
Analysts project a significant 8.4% year-over-year increase in diluted earnings per share to $10.69 for the upcoming quarter.
Management has set a clear target range for adjusted fiscal 2027 earnings per share between $44.20 and $45.00, indicating confidence in profitability.
McKesson Corporation is preparing to report its fiscal second-quarter 2027 earnings on Wednesday, November 4, 2026, following the market close. Analysts anticipate a significant beat in performance, with consensus estimates projecting earnings of $10.72 per share and revenue reaching $109.90 billion.
These expected figures represent an 8.7% increase in earnings and a 6.5% rise in revenue compared to the same quarter last year. The company previously reported fiscal first-quarter results on August 5, 2026, where it posted $9.93 per share in earnings and $105.38 billion in revenue.
Investors are closely watching this upcoming report to determine if McKesson can sustain its recent track record of beating consensus estimates in six of the last eight quarters. The primary focus will be on whether the company can successfully convert growing revenue into higher profits while maintaining its full-year guidance amidst broader market sentiment.
๐ McKesson reports Q2 2027 results after market close Nov 4, 2026.
๐ฐ Analysts expect $10.72 EPS and $109.9B revenue for the quarter.
๐ Earnings projected to grow 8.7% while revenue rises 6.5% year-over-year.
๐ McKesson beat estimates in six of its last eight quarters.
โ๏ธ Investors watch margin conversion and full-year outlook guidance closely.
๐ McKesson is scheduled to release fiscal second-quarter 2027 results after the market close on Wednesday, November 4, 2026.
๐ฐ Analysts expect earnings of $10.72 per share and revenue of $109.90 billion for the upcoming quarter.
๐ Expected performance implies an 8.7% growth in earnings and a 6.5% increase in revenue year-over-year.
๐ McKesson has exceeded consensus earnings estimates in six of its last eight quarters, establishing a strong recent track record.
๐ The upcoming report will provide critical insights into demand across pharmaceutical distribution, specialty-care, and medical-surgical operations.
โ๏ธ Key investor attention is focused on the company's ability to convert revenue growth into sustained profit margins.
๐ Management comments regarding the full-year outlook will be a central point of interest during the earnings call.
Bullish Signals
Beat earnings estimates in 6 of last 8 quarters.
Q2 EPS projected at $10.72 with $109.9B revenue.
Bullish Signals
McKesson has demonstrated a strong track record, exceeding consensus earnings estimates in six of its last eight quarters.
Analysts project robust growth with expected earnings of $10.72 per share and revenue of $109.90 billion for the fiscal second quarter.
McKesson Corporation announced a significant strategic investment of USD 1.4 billion to acquire a minority interest in Option Care Health, a move detailed in an agreement dated October 6, 2026. This transaction values the healthcare services provider at approximately USD 5.8 billion and establishes a joint ownership structure where CD&R will hold roughly 51% of Option Care Health while McKesson retains approximately 49%. The deal is structured to allow Option Care Health to remain an independent entity led by its existing management team, signaling McKesson's continued expansion into the healthcare services sector.
The corporate development is expected to close in the first half of calendar year 2027, pending customary closing conditions such as stockholder and regulatory approvals. This acquisition represents a major capital allocation decision for McKesson, aiming to strengthen its position in the home health and hospice care market. The company confirmed the agreement through its investor relations channel, highlighting the strategic importance of this partnership.
Separately, McKesson stock was trading at EUR 896.00 during weekend sessions on October 18, 2026, according to data from Lang & Schwarz. The exchange displayed a bid of EUR 894.20 and an ask of EUR 897.80 at the time of reporting. This weekend trading activity reflects market interest in the stock outside of standard business hours, though the primary news driver remains the substantial investment in Option Care Health.
๐ค McKesson invests USD 1.4B for 49% minority stake in Option Care Health.
๐ฐ Deal values Option Care at USD 5.8B with CD&R holding 51%.
๐ Transaction expected to close in first half of calendar year 2027.
๐ฅ Option Care remains separate company led by its own management team.
๐ข Agreement confirms major expansion into healthcare services for McKesson.
๐ค McKesson agreed to invest USD 1.4 billion for a minority stake in Option Care Health under an October 6, 2026 agreement.
๐ฐ The transaction values Option Care Health at approximately USD 5.8 billion with CD&R holding 51% and McKesson holding 49%.
๐ The deal is expected to close in the first half of calendar year 2027 subject to regulatory and stockholder approvals.
๐ฅ Option Care Health will remain a separate company led by its own management team following the investment.
๐ McKesson stock traded at EUR 896.00 during weekend sessions on October 18, 2026, according to Lang & Schwarz data.
๐ข The agreement was confirmed via McKesson investor relations and represents a major expansion into healthcare services.
Bullish Signals
Investing USD 1.4B in Option Care Health expansion.
Diversifying revenue into high-growth home health care.
Risk Factors
$1.4B investment strains near-term cash flow.
Bullish Signals
McKesson is executing a major strategic expansion by investing USD 1.4 billion in Option Care Health, signaling strong confidence in the home health and hospice care market.
The acquisition of a minority interest in Option Care Health allows McKesson to diversify its revenue streams beyond pharmaceutical distribution into high-growth healthcare services.
Risk Factors
The USD 1.4 billion investment represents a significant capital outlay that will impact McKesson's cash flow and balance sheet in the near term.
McKesson Corporation (NYSE: MCK) reported a significant divergence between top-line growth and profitability in the most recent quarter, with revenue rising 7.70% to $410.98 billion while net earnings fell 21.70% to $4.59 billion. This decline in profit occurred despite the company maintaining its massive distribution network, highlighting the extreme sensitivity of McKesson's thin margins to minor fluctuations in pricing spreads.
The company operates with a net margin of just 1.12%, earning approximately one cent for every dollar of sales processed through its national drug distribution system. This asset-light model has allowed McKesson to retire its equity entirely, resulting in a negative book value per share of $36.55, yet the market values the company at $94.37 billion based on its dominant market position and lack of viable competitors.
McKesson's financial structure includes $6.8 billion in cash against $6.85 billion in operating expenses, leaving no capital spending gap, while debt stands at $11.8 billion. The stock trades at a price-to-sales ratio of 0.26 and a forward P/E of 19.72x, reflecting investor confidence in the durability of its economic moat despite the lack of equity buffer to absorb earnings volatility.
๐ Net earnings dropped 21.70% as operating spread per package contracted sharply.
๐ฐ Revenue reached $410.98B but net margin fell to just 1.12%.
๐ฆ Cash of $6.8B covers expenses, leaving negative book value of $36.55.
๐ก๏ธ Dominant US drug distribution market creates high barriers for new rivals.
๐ Stock rose 21.72% over twelve months despite recent earnings misses.
๐ McKesson reported a sharp 21.70% decline in net earnings while revenue grew 7.70%, driven by a contraction in the operating spread per package.
๐ฐ The company generated $4.59 billion in profit on $410.98 billion in revenue, resulting in a net margin of just 1.12%.
๐ฆ McKesson holds $6.8 billion in cash against $6.85 billion in operating expenses, effectively retiring its equity and leaving a negative book value per share of $36.55.
๐ก๏ธ The company maintains a dominant market position with three firms controlling most US drug distribution, creating a high barrier to entry for new competitors.
๐ The stock traded near $916 on October 5, up 21.72% over the last twelve months, despite recent earnings misses.
๐ McKesson's operating margin of 1.35% leaves very little buffer above the net margin, making the business highly sensitive to spread changes.
๐๏ธ Hedge fund ownership increased slightly in Q2 2026, with 77 funds holding a combined stake value of $4.33 billion.
Bullish Signals
Asset-light model enabled full equity retirement with massive market presence.
Durable moat as one of only three national drug distributors.
Holds $6.8B cash vs $6.85B expenses, funding buybacks easily.
Stock up 21.72% YTD at forward P/E of 19.72x.
Risk Factors
Net earnings fell 21.70% despite revenue growth.
Thin 1.12% margins vulnerable to pricing shifts.
Bullish Signals
McKesson operates an asset-light distribution model that has allowed it to retire its equity entirely, resulting in a negative book value per share while maintaining a massive market presence.
The company possesses a durable economic moat as one of only three firms capable of building the necessary national warehouse and approval network for drug distribution.
McKesson holds $6.8 billion in cash against $6.85 billion in operating expenses, demonstrating strong liquidity and an ability to fund buybacks without capital spending gaps.
The stock has gained 21.72% over the last twelve months, trading at a forward P/E of 19.72x which reflects market confidence in its long-term cash flow generation.
Risk Factors
Net earnings fell 21.70% while revenue grew 7.70%, indicating that the company's thin margins are highly vulnerable to minor shifts in pricing spreads.
The business operates with a net margin of only 1.12%, meaning a few basis points of spread movement can significantly impact annual profitability.
As of September 21, 2026, McKesson Corporation (MCK) trades at $874.65, trading below the consensus Wall Street price target of $1,000.00 set by 18 analysts, which implies a potential upside of approximately 14.3%. The stock is currently rated 'Hold' by CleaRank Financial AI with a fair value estimate of $999.99, while technical indicators show the price trading above its 50-day average at an RSI of 44.
McKesson has demonstrated operational resilience by exceeding analyst EPS estimates in the quarter ending June 2026 with a 4.09% surprise. However, the company faces significant headwinds regarding insider activity and capital efficiency. Insiders have sold $83.7 million worth of stock with no reported purchases, signaling potential management caution. Furthermore, McKesson's return on equity stands at a concerning -570.98%, which is significantly worse than the sector average and raises questions about profitability.
Long-term simulations project varying outcomes for MCK investors. A historical backtest shows a $10,000 investment in September 2016 would be worth approximately $52,563 today, outperforming the S&P 500 benchmark which returned about $35,293. CleaRank's 10-year Monte Carlo simulation projects a base case growth to roughly $31,422 by 2036, with a bull case near $102,728 and a bear case around $9,611, assuming no dividends are reinvested.
๐ MCK trades at $874.65, implying 14.3% upside vs $1,000 target.
๐ Company beat EPS estimates by 4.09% in June 2026 quarter.
๐ฐ Insiders sold $83.7M stock with no reported purchases recently.
โ ๏ธ MCK return on equity is -570.98%, worse than sector average.
๐ $10,000 investment since 2016 grew to $52,563 outperforming S&P 500.
๐ McKesson trades at $874.65, below the consensus analyst price target of $1,000.00, suggesting a potential 14.3% upside.
๐ The company recently exceeded analyst EPS estimates with a 4.09% surprise in the quarter to June 2026.
๐ฐ Insiders have sold $83.7 million worth of stock with no reported purchases, indicating heavy insider selling.
โ ๏ธ McKesson's return on equity is -570.98%, significantly worse than the sector average and raising capital efficiency concerns.
๐ Historical data shows a $10,000 investment in MCK since 2016 grew to $52,563, outperforming the S&P 500's $35,293.
๐ฎ Monte Carlo simulations project a base case value of $31,422 by 2036 for a $10,000 investment made today.
Bullish Signals
Beat EPS estimates with 4.09% surprise in Q2 2026.
McKesson has a track record of exceeding analyst EPS estimates, most recently with a 4.09% surprise in the quarter to June 2026.
The stock trades below the consensus Wall Street price target of $1,000.00 across 18 analysts, suggesting a 14.3% potential upside.
Risk Factors
Insiders have sold $83.7 million worth of stock with no reported purchases, signaling heavy insider selling and potentially indicating a lack of management confidence.
McKesson's return on equity stands at a concerning -570.98%, which is significantly worse than the sector average and raises questions about capital efficiency and profitability.
McKesson Corporation reported a robust quarter ending August 5, 2026, with revenue reaching USD 105.38 billion and adjusted earnings per share (EPS) of USD 9.93. This performance exceeded the consensus estimate of USD 9.56, marking a year-over-year EPS increase of USD 1.67 compared to the same quarter last year when EPS was USD 8.26.
The company's stock price responded positively to these results, trading at USD 907.35 on Friday, which is near its 52-week high of USD 999.00. The share price remains above both its 50-day moving average of USD 848.13 and its 200-day moving average of USD 843.09, indicating sustained investor interest despite the premium valuation.
Analysts on MarketBeat project an expected EPS of USD 44.65 for the current fiscal year, while McKesson has provided FY 2027 guidance ranging between USD 44.2 and USD 45.0 per share. The company maintains its position as a major healthcare distribution and services provider, leveraging its massive scale to generate significant market value even with a net margin of 1.12 percent.
๐ McKesson revenue hit $105.38B, up 7.7% year-over-year.
๐ฐ Adjusted EPS reached $9.93, beating estimates by $0.37.
๐ Stock traded at $907.35, near its 52-week high.
๐ฏ FY 2027 EPS guidance set between $44.2 and $45.0.
๐ McKesson reported USD 105.38 billion in revenue for the quarter ended August 5, 2026, representing a 7.7 percent increase from the prior year.
๐ฐ The company delivered adjusted EPS of USD 9.93, beating the consensus estimate of USD 9.56 and showing a year-over-year gain of USD 1.67 per share.
๐ Stock price reached USD 907.35 on Friday, trading near its 52-week high of USD 999.00 and above both key moving averages.
๐ฏ Management provided FY 2027 EPS guidance between USD 44.2 and USD 45.0, aligning closely with analyst expectations of USD 44.65.
๐ข As a leading healthcare distributor, McKesson continues to leverage its massive scale, evidenced by over USD 105 billion in quarterly revenue.
๐ The company maintains a net margin of 1.12 percent, which translates into substantial market capitalization exceeding USD 105 billion.
Bullish Signals
McKesson beat analyst consensus estimates with adjusted EPS of USD 9.93 versus the expected USD 9.56 for the quarter ended August 5, 2026.
Revenue grew 7.7 percent year-over-year to reach USD 105.38 billion, demonstrating continued top-line expansion in the healthcare distribution sector.
The stock price rallied to USD 907.35, trading near its 52-week high of USD 999.00 and validating the market's positive reaction to the strong quarterly results.
Management provided FY 2027 EPS guidance of USD 44.2 to USD 45.0, which aligns well with external analyst expectations of USD 44.65 for the current fiscal year.
McKesson Corporation announced a $2.25 billion acquisition of privately held Precision Medicine Group, a move designed to significantly strengthen its Oncology & Multispecialty segment. The deal integrates Precision Medicine's clinical research, laboratory testing, and commercialization services into McKesson's portfolio, aiming to enhance clinical trial execution and broaden service offerings for biopharma clients.
This acquisition aligns with McKesson's broader strategy of shedding non-core assets to fund investments in higher-growth areas like oncology. The company recently sold a minority stake in its medical-surgical solutions business to Apollo Funds for $1.25 billion, demonstrating a disciplined approach to capital recycling rather than relying on new debt. Precision Medicine will join the Oncology & Multispecialty segment, which already reported robust revenue growth.
Analysts note that while the deal solidifies McKesson's long-term oncology strategy, its financial impact is expected to be gradual due to the size of the target relative to McKesson's overall scale. Key challenges include regulatory review timelines, integration risks associated with adding new capabilities, and the need to prove scalability and synergy creation to justify the investment cost.
McKesson's Oncology & Multispecialty segment demonstrated strong performance in the first quarter of fiscal 2026, with revenue jumping 33% to $14.2 billion. Hedge fund holdings in McKesson increased slightly in the second quarter of 2026, reflecting continued institutional interest despite the execution uncertainties surrounding the acquisition's completion and integration.
๐ McKesson agrees to acquire Precision Medicine Group for $2.25 billion.
๐ฐ Deal funded by Apollo Funds sale of medical-surgical stake for $1.25B.
๐ Oncology segment revenue surged 33% YoY to $14.2B in Q1 fiscal 2026.
โณ Closing timeline uncertain due to potential regulatory review or integration delays.
๐ค Analysts caution on scalability and synergy validation for the acquisition.
๐ McKesson agreed to acquire Precision Medicine Group for approximately $2.25 billion to bolster its Oncology & Multispecialty segment.
๐ฌ The target provides clinical research, laboratory testing, and commercialization services that will integrate into McKesson's existing portfolio.
๐ฐ The acquisition is funded by capital recycling from the recent sale of a minority stake in medical-surgical solutions to Apollo Funds for $1.25 billion.
๐ McKesson's Oncology & Multispecialty segment revenue surged 33% year-over-year to $14.2 billion in Q1 fiscal 2026.
โณ No specific closing timeline was provided, introducing potential regulatory review or integration delays before benefits materialize.
๐ค Analysts from JPMorgan and Leerink Partners caution that investors need clarity on scalability and synergy creation to validate the deal's growth impact.
๐ The $2.25 billion investment is considered a modest bolt-on unlikely to drive immediate transformative results for the broader company.
โ ๏ธ Integration risks exist as McKesson combines new clinical capabilities with its established Oncology & Multispecialty business operations.
๐ฆ Hedge fund ownership of McKesson rose to 77 funds in Q2 2026, with total holdings valued at $4.33 billion.
๐ฏ The deal extends a proven strategy where management is actively exiting non-core assets to invest in specialty care growth.
Bullish Signals
McKesson is executing a disciplined capital recycling strategy by selling non-core assets like its medical-surgical solutions stake to fund high-growth investments.
The Oncology & Multispecialty segment, the target for integration, demonstrated exceptional growth with revenue jumping 33% to $14.2 billion in Q1 fiscal 2026.
The acquisition of Precision Medicine Group directly enhances McKesson's clinical research and commercialization services for biopharma customers.
Institutional confidence remains strong, evidenced by an increase in hedge fund holdings to 77 funds in Q2 2026 compared to 73 in the prior quarter.
Risk Factors
The acquisition lacks a stated completion timeline, creating uncertainty regarding regulatory review duration and potential integration delays.
Analysts warn that the strategic rationale does not automatically guarantee financial payoff, requiring proof of scalability and synergy creation.
Integration risks are present as McKesson must effectively combine new clinical capabilities with its existing Oncology & Multispecialty operations.
The $2.25 billion deal is a modest bolt-on relative to the company's scale, limiting its potential for immediate transformative impact on overall earnings.
McKesson Corporation (MCK) is a global healthcare distribution giant with a history of consistent dividend growth, having increased its payout for 26 consecutive years to earn Dividend Aristocrat status. As of September 2026, the company pays a quarterly dividend of $0.94, resulting in an annualized rate of $3.40 per share and a current yield of 0.37% based on a stock price near $908.
The company operates through four primary segments: U.S. Pharmaceutical distribution, Medical-Surgical Solutions, international operations, and Prescription Technology Solutions (RxTS). This diversified business model spans pharmaceuticals, medical supplies, and technology services for pharmacies and healthcare providers, supported by a conservative 8.6% dividend payout ratio that prioritizes earnings retention over current yield expansion.
McKesson's dividend growth has been robust historically, achieving a compound annual growth rate (CAGR) of 10.3% from 2011 to 2025. While the current yield is low compared to high-yield alternatives, the stock offers stability with a beta of 0.307 and provides investors exposure to recurring demand in healthcare distribution through a strategy focused on long-term dividend expansion rather than immediate income generation.
๐ McKesson raised dividend for 26th consecutive year as Dividend Aristocrat.
๐ฐ Quarterly dividend is $0.94 with annualized rate of $3.40.
๐ Current yield is 0.37%, above the 5-year average of 0.26%.
๐ก๏ธ Conservative 8.6% payout ratio retains earnings for future growth.
๐ Dividend CAGR reached 10.3% from 2011 to 2025.
๐ McKesson has increased its dividend for 26 consecutive years, securing Dividend Aristocrat status.
๐ฐ The company pays a quarterly dividend of $0.94 per share with an annualized rate of $3.40.
๐ The current dividend yield is 0.37%, which is low but sits above the 5-year average of 0.26%.
๐ก๏ธ McKesson maintains a conservative 8.6% payout ratio, retaining most earnings to fund future growth.
๐ Historical dividend growth from 2011 to 2025 shows a CAGR of 10.3%, with per-share payments rising from $0.78 to $3.06.
๐ข The business spans four segments including U.S. Pharmaceutical, Medical-Surgical Solutions, international markets, and RxTS.
๐ McKesson has a low beta of 0.307, indicating the stock moves significantly less than the broader market.
Bullish Signals
The company has achieved Dividend Aristocrat status with 26 consecutive years of dividend increases.
McKesson maintains a highly conservative 8.6% payout ratio, providing substantial room to sustain or grow the dividend without financial strain.
Historical performance shows a strong 10.3% compound annual growth rate (CAGR) in dividends from 2011 to 2025.
The current yield of 0.37% is higher than the 5-year average of 0.26%, indicating recent price appreciation relative to dividend payments.
Risk Factors
The current dividend yield of 0.37% is very low, offering minimal immediate income for investors seeking high-yield returns.
The exceptionally low payout ratio means the stock's total return relies heavily on share price appreciation rather than current cash flow distribution.
McKesson (MCK) has regained investor attention following strategic portfolio changes, including its exit from Canada and Norway, and the planned spin-off of its Medical-Surgical unit. These moves are accompanied by a raised fiscal 2027 outlook, signaling a refocus on core growth drivers within the U.S. market.
The company is shifting its portfolio to lean more heavily into U.S. pharmaceuticals and oncology services. This strategic pivot aims to improve the quality of its revenue mix and position the business for higher operating margins and sustained earnings growth through recent acquisitions like Core Ventures and PRISM Vision.
Simply Wall Street analysis suggests McKesson is currently undervalued with a fair value target of $980.80, compared to a recent closing price near $906. The narrative highlights potential upside driven by specialty pharmaceutical growth, disciplined share count reduction, and the rerating of the stock based on improved fundamentals.
๐ McKesson raised fiscal 2027 outlook after strategic refocus on core growth.
๐ Exiting Canada and Norway to streamline operations and focus on US.
๐ฅ Spinning off Medical-Surgical unit to concentrate resources on high-margin segments.
๐ Acquiring Core Ventures and PRISM Vision expands provider network and services.
๐ Stock gained 22.61% in 90 days with $980.80 analyst target price.
๐ McKesson has raised its fiscal 2027 outlook following a strategic refocus on core business growth.
๐ The company is executing portfolio changes including an exit from Canada and Norway to streamline operations.
๐ฅ McKesson plans to spin off its Medical-Surgical unit to concentrate resources on high-margin segments.
๐ Recent acquisitions of Core Ventures and PRISM Vision are expanding the provider network and service portfolio.
๐ The stock has delivered a 22.61% return over the last 90 days and a 31.62% one-year total shareholder return.
๐ฏ Analyst fair value estimates suggest a target price of $980.80, implying the stock is undervalued at current levels.
๐บ๐ธ The portfolio is being reshaped to lean more heavily into U.S. pharmaceuticals and oncology services.
โ๏ธ Strategic shifts aim to improve revenue mix quality and drive higher operating margins over time.
Bullish Signals
McKesson has raised its fiscal 2027 outlook, signaling confidence in future earnings power and cash returns.
The company is increasing adoption of specialty and oncology pharmaceuticals to improve revenue mix quality.
Recent acquisitions of Core Ventures and PRISM Vision are expanding the provider network and service portfolio.
Strategic portfolio changes including exits from international markets aim to focus on core U.S. businesses.
The planned spin-off of the Medical-Surgical unit is intended to sharpen focus on higher-margin segments.
McKesson is pursuing disciplined share count reduction which supports a potential stock rerating.
Risk Factors
Investors must monitor ongoing policy pressure on drug pricing which could impact revenue growth.
There is a risk that distributors or payers may bring more volume in-house, challenging McKesson's distribution thesis.
McKesson Corporation (MCK) is presented as a compelling long-term compounder with a share price of $763.91 as of June 23, 2026. Despite a recent decline from nearly $1,000 driven by a fiscal 2026 fourth-quarter revenue miss, the article argues the core investment thesis remains intact due to its dominant position in pharmaceutical distribution and disciplined capital allocation.
Operating within a rational oligopoly alongside Cencora and Cardinal Health, McKesson leverages scale and supply chain reliability. The company generates substantial cash flow through an asset-light model, producing $5.4 billion in free cash flow for fiscal 2026 while reducing its share count by over 60% over the past two decades to enhance per-share growth.
Strategically shifting toward higher-margin businesses, McKesson's Oncology and Multi-Specialty segment delivered 31% revenue growth and 53% operating profit growth in fiscal 2026. With a return on invested capital of approximately 70% and a newly authorized $5 billion share repurchase program, conservative valuations suggest intrinsic value between $885 and $1,275 per share.
๐ Shares dropped to $763.91 after missing Q4 revenue targets.
๐๏ธ Dominates U.S. pharma distribution alongside Cencora and Cardinal Health.
๐ Oncology segment grew revenue 31% and profits 53% in Q4.
๐ฏ Intrinsic value estimates suggest 18% to 70% upside potential.
๐ MCK shares traded at $763.91 on June 23, 2026, down from nearly $1,000 following a fiscal 2026 Q4 revenue miss.
๐๏ธ McKesson operates in a U.S. pharmaceutical distribution oligopoly with Cencora and Cardinal Health, controlling most of the market.
๐ฐ The company generated $5.4 billion in free cash flow during fiscal 2026 despite low operating margins of roughly 1.5%.
๐ Management has reduced share count by more than 60% over two decades while tying compensation to return on invested capital.
๐ The Oncology and Multi-Specialty segment achieved 31% revenue growth and 53% operating profit growth in fiscal 2026.
๐ Return on invested capital reached approximately 70%, highlighting efficient capital deployment across the business.
๐ธ A newly authorized $5 billion share repurchase program signals a commitment to returning value to shareholders.
๐ฏ Conservative intrinsic value estimates range from $885 to $1,275 per share, implying 18% to 70% upside.
Bullish Signals
McKesson dominates pharmaceutical distribution with scale advantages.
$5.4B free cash flow generated in fiscal 2026.
Share count reduced over 60% via buybacks.
Onco segment grew revenue 31% and profit 53%.
70% return on invested capital shows efficiency.
$5B new share repurchase program authorized.
Risk Factors
Missed Q4 2026 revenue target caused share price drop from ~$1,000.
Low 1.5% operating margins limit profitability vs higher-margin peers.
Bullish Signals
McKesson is described as a dominant player in pharmaceutical distribution with significant competitive advantages through scale and deep customer relationships.
The company generated $5.4 billion in free cash flow for fiscal 2026, demonstrating strong cash generation capabilities despite low operating margins.
Management has aggressively repurchased stock over the past two decades, reducing share count by more than 60% to enhance per-share growth.
The high-margin Oncology and Multi-Specialty segment delivered 31% revenue growth and 53% operating profit growth in fiscal 2026.
McKesson benefits from favorable long-term tailwinds including an aging U.S. population and growing demand for GLP-1 therapies.
The company achieved a return on invested capital of approximately 70%, indicating highly efficient use of capital.
A newly authorized $5 billion share repurchase program provides additional support to shareholder value.
Risk Factors
McKesson recently missed its fiscal 2026 fourth-quarter revenue target, contributing to a significant decline in share price from nearly $1,000.
The company operates with low operating margins of roughly 1.5%, which limits profitability compared to higher-margin healthcare segments.
AdvisorShares Investments LLC reduced its position in McKesson Corporation (NYSE: MCK) by 8.4% in the first quarter, selling 782 shares to hold a remaining stake of 8,520 shares valued at $7.37 million. While AdvisorShares decreased its exposure, other institutional investors like Walter Public Investments Inc. significantly increased their stakes, with Walter adding 9,417 shares and Astoria Portfolio Advisors boosting holdings by 5.8%. These filings highlight a mixed sentiment among hedge funds regarding the healthcare distributor's stock.
McKesson reported quarterly earnings on May 7th that beat analyst expectations for EPS at $11.69 versus a consensus of $11.56, though revenue of $96.30 billion missed estimates by nearly $5 billion. The company achieved a 6.0% year-over-year revenue increase and maintains a forward guidance range of $43.80 to $44.60 EPS for fiscal 2027. Analysts currently project an average consensus target price of $960.53, with the stock trading at a yield of 0.4% following its recent dividend payment.
Insider trading activity shows significant selling pressure from top executives in June. CEO Brian S. Tyler sold 8,463 shares worth approximately $6.56 million under a pre-arranged Rule 10b5-1 plan, while CAO Napoleon B. Rutledge, Jr. sold 133 shares for about $101,612. Over the last ninety days, insiders have collectively sold over 20,000 shares worth more than $15.5 million, representing a notable reduction in direct ownership by company leadership.
๐ AdvisorShares cut holdings by 8.4% to 8,520 shares valued at $7.37 million.
๐ Walter Public increased stake by 118.2% with 9,417 shares worth over $15 million.
Hsbc Holdings PLC increased its stake in McKesson Corporation (NYSE: MCK) by 6.0% in the fourth quarter, purchasing an additional 15,594 shares to hold a total of 275,912 shares valued at approximately $226.8 million. This move represents a 0.23% ownership stake for Hsbc. Several other institutional investors also adjusted their positions during the quarter, with Rockefeller Capital Management increasing holdings by 42.9% and multiple new positions established by Cornerstone Planning, Union Savings Bank, Bayban, and World Investment Advisors.
McKesson reported quarterly earnings on May 7th, delivering $11.69 per share which beat analyst consensus estimates of $11.56. However, the company's revenue of $96.30 billion fell short of the expected $101.35 billion, representing a year-over-year increase of only 6.0%. The firm reported a net margin of 1.18% and a negative return on equity of 345.35%. Analysts currently anticipate an EPS of $44.28 for the current fiscal year.
Recent analyst activity shows mixed signals regarding McKesson's valuation and outlook. Wall Street Zen downgraded the stock from a 'buy' to a 'hold' rating in late June, while JPMorgan Chase lowered its price target from $1,107 to $1,015. Conversely, UBS raised its price target to $1,050 with a 'buy' rating, and Deutsche Bank maintained a 'buy' rating with an objective of $875. The average analyst price target stands at $960.53 based on data from MarketBeat.com.
Corporate insiders have executed significant stock sales recently under pre-arranged Rule 10b5-1 trading plans. EVP Michele Lau sold 3,550 shares in late May for approximately $2.7 million, while CEO Brian S. Tyler sold 8,463 shares in mid-June for about $6.56 million. Collectively, insiders have sold over 20,000 shares worth roughly $15.5 million in the last quarter. The company recently paid a quarterly dividend of $0.82 per share on June 1st, resulting in an annualized yield of 0.4%.
iA Global Asset Management Inc. significantly increased its stake in McKesson Corporation (NYSE: MCK) by purchasing an additional 6,371 shares during the first quarter, bringing total holdings to 6,394 shares valued at $5.53 million. While this specific increase is mathematically massive due to a tiny prior position, other institutional investors like University of Texas and Swiss RE also established new positions in the fourth quarter, indicating continued institutional interest despite hedge funds holding 85.07% of the stock.
Analyst sentiment remains mixed with conflicting price targets and ratings. JPMorgan Chase lowered its price objective to $1,015 while maintaining an overweight rating, whereas UBS raised its target to $1,050 with a buy rating. Conversely, Wells Fargo cut its target to $812 with an equal weight rating, and Wall Street Zen downgraded the stock to a hold. The consensus average price target stands at $960.53 based on data from MarketBeat.
Recent insider activity shows executives selling shares under pre-arranged Rule 10b5-1 trading plans. CAO Napoleon B. Rutledge, Jr. sold 133 shares for approximately $101,612, while EVP Michele Lau sold 3,550 shares for roughly $2.7 million. In total, insiders sold 20,285 shares valued at $15.5 million in the last quarter, leaving only 0.06% of the stock owned by insiders.
Financially, McKesson reported quarterly earnings of $11.69 per share, beating estimates of $11.56, though revenue of $96.3 billion missed analyst expectations of $101.35 billion. The company maintains a market cap of $90.03 billion and has set FY 2027 guidance between $43.80 and $44.60 EPS. It recently paid a quarterly dividend of $0.82 per share, resulting in an annualized yield of 0.4%.
๐ iA Global increased MCK stake by 27,700% to $5.53 million.
๐๏ธ University of Texas and Swiss RE established new positions.
๐ Analysts lowered price targets; consensus is now $960.53.
๐ฐ Q1 EPS beat estimates at $11.69 despite revenue miss.
๐ธ Insiders sold 20,285 shares worth $15.5 million last quarter.
๐ iA Global Asset Management Inc. increased its MCK stake by 27,700%, holding 6,394 shares worth $5.53 million after buying 6,371 new shares.
๐๏ธ Multiple institutional investors including University of Texas and Swiss RE established new positions in the fourth quarter.
๐ JPMorgan Chase lowered its price target to $1,015 while UBS raised theirs to $1,050 with a buy rating.
๐ Wells Fargo reduced its price objective to $812 and assigned an equal weight rating to the stock.
๐ Wall Street Zen downgraded McKesson from a buy to a hold rating in late June.
๐ฐ The consensus analyst price target for MCK is currently set at $960.53.
๐ McKesson reported Q1 earnings of $11.69 EPS, beating the $11.56 consensus estimate.
๐ Revenue came in at $96.3 billion, missing analyst estimates of $101.35 billion for the quarter.
๐ Year-over-year revenue growth remained positive at 6.0% despite the miss in absolute numbers.
๐ธ Insiders sold a total of 20,285 shares valued at $15.5 million over the last quarter.
๐ CAO Napoleon B. Rutledge, Jr. sold 133 shares for $101,612 under a Rule 10b5-1 plan.
๐ EVP Michele Lau sold 3,550 shares for $2.7 million, reducing her ownership by over 50%.
๐ต The company paid a quarterly dividend of $0.82 per share with an ex-dividend date of June 1st.
๐ FY 2027 earnings guidance is set between $43.80 and $44.60 per share.
๐ The stock trades at a PEG ratio of 1.24 with a market capitalization of $90.03 billion.
Bullish Signals
iA Global added 6,371 shares to $5.53M holdings.
University of Texas and Swiss RE opened new positions.
McKesson Corporation (NYSE: MCK) maintains a constructive analyst consensus ahead of its upcoming earnings season, with the majority of large Wall Street firms holding a 'Moderate Buy' rating. Data compiled by MarketBeat indicates an average price target of $960.53, suggesting approximately 29% upside from the stock's recent opening price of $745.12 on June 23, 2026. This target is anchored near the upper end of the stock's 52-week trading range, which spans from a low of $637 to a high of $999.
Technical indicators show the shares are currently in a consolidation phase, trading below both its 50-day moving average ($785.38) and its 200-day moving average ($841.72). While Deutsche Bank recently reiterated a buy rating with a specific objective of $875, institutional positioning has seen notable shifts, including Generate Investment Management reducing its stake by 85.7% in the first quarter.
Fundamentally, McKesson continues to generate revenue through the distribution of pharmaceuticals and medical supplies across North America and Europe, alongside technology solutions for healthcare providers. The company recently highlighted a strategic minority investment with Apollo funds in its Medical-Surgical Solutions unit, reinforcing the importance of this segment which covers essential items like syringes and operating room supplies.
๐ Analysts maintain a Moderate Buy rating with a $960.53 price target.
๐ Stock trades below 50-day and 200-day moving averages at $745.12.
๐ฆ Deutsche Bank reiterates buy rating with a $875 price objective.
๐ Generate Investment Management reduced stake by 85.7% in Q1.
๐ฌ Company invests minority interest in Apollo for Medical-Surgical Solutions unit.
๐ Analysts maintain a 'Moderate Buy' consensus for McKesson with an average price target of $960.53, implying roughly 29% upside from the current trading level.
๐ The stock recently opened at $745.12, trading below its 50-day moving average ($785.38) and 200-day moving average ($841.72), indicating a period of consolidation.
๐ฆ Deutsche Bank reiterated a buy rating with a price objective of $875, supporting the broader moderate buy stance despite being below the consensus target.
๐ Institutional ownership saw significant changes as Generate Investment Management reduced its stake by 85.7% in the first quarter according to recent SEC filings.
๐ผ McKesson operates with a substantial market capitalization and remains relevant for major US benchmarks, though it is not part of the S&P 500 healthcare distributors sub-index.
๐ฌ The company recently announced a strategic minority interest investment with Apollo funds specifically targeting its Medical-Surgical Solutions unit.
๐ฅ McKesson's revenue model relies on distributing branded and generic pharmaceuticals, medical-surgical supplies, and providing technology solutions for pharmacies and hospitals.
๐ The stock's 52-week range spans from $637 to $999, with the consensus target positioned close to the historical high end of this band.
Bullish Signals
Analysts maintain 'Moderate Buy' rating with $960.53 target.
Deutsche Bank reiterates buy with $875 price objective.
Apollo funds invest in high-growth Medical-Surgical Solutions unit.
Risk Factors
Major stake reduced by 85.7% in Q1.
Trading below 50-day and 200-day moving averages.
Bullish Signals
Analysts maintain a 'Moderate Buy' rating with an average price target of $960.53, representing approximately 29% upside potential from the recent opening price.
Deutsche Bank has reiterated a buy rating with a specific price objective of $875, providing support for the stock's valuation despite being below the broader consensus.
McKesson recently secured a strategic minority interest investment from Apollo funds in its Medical-Surgical Solutions unit, highlighting strong confidence in this high-growth segment.
Risk Factors
Generate Investment Management significantly reduced its stake by 85.7% in the first quarter, indicating a notable shift in institutional positioning for some major funds.
The stock is currently trading below both its 50-day and 200-day moving averages, suggesting it is in a consolidation phase below longer-term trend levels.
McKesson Corp. (MCK) shares rallied 2.56% to $763.91 on Tuesday, marking a significant outperformance against the broader market which saw the S&P 500 fall 1.44% and the Dow Jones Industrial Average drop slightly.
This price increase effectively snapped a three-day losing streak for the healthcare distributor's stock, highlighting its resilience during an otherwise poor trading session for equities.
๐ MCK shares rose 2.56% to $763.91 on Tuesday.
๐ Stock rallied despite S&P 500 falling 1.44%.
๐ Rally ended a three-day losing streak for MCK.
๐ฐ MCK outperformed competitors in negative market conditions.
๐ McKesson Corp. (MCK) shares rose 2.56% to close at $763.91 on Tuesday.
๐ The rally occurred despite a broader market decline with the S&P 500 falling 1.44%.
๐ This move ended a three-day losing streak for the company's stock price.
๐ฐ The stock outperformed competitors during a negative market environment.
Bullish Signals
McKesson rallied 2.56% while market fell.
Stock snapped three-day losing streak.
Risk Factors
Three-day losing streak shows recent weakness.
S&P 500 fell 1.44% while stock rallied.
Bullish Signals
McKesson Corp. demonstrated relative strength by rallying 2.56% while the broader market declined, indicating investor confidence in its specific business fundamentals or recent developments.
The stock successfully snapped a three-day losing streak, suggesting a potential stabilization or reversal of recent negative price momentum.
Risk Factors
McKesson Corp. had suffered a three-day losing streak prior to Tuesday's rally, indicating recent weakness in investor sentiment or performance.
The company's positive move occurred during an all-around poor trading session where the S&P 500 fell 1.44%, suggesting the stock is currently isolated from broader market trends.
McKesson Corporation (NYSE: MCK) is a leading diversified healthcare services company with a market capitalization of $87.88 billion, operating primarily in North American Pharmaceutical and Oncology & Multispecialty segments. Currently trading at $750.63, the stock has dipped slightly but maintains a significant growth potential highlighted by analyst consensus.
Analysts project an average target price of $941.40, implying approximately 25.41% upside from current levels. The company demonstrates robust financial health with revenue growth of 6.00% and substantial free cash flow of $5.66 billion, providing flexibility for investment and capital returns despite a modest dividend yield of 0.44%.
Sentiment among analysts is overwhelmingly positive, reflected in 15 buy ratings versus only 2 hold ratings, with no sell ratings recorded. While the stock trades below its 50-day and 200-day moving averages suggesting short-term technical weakness, an RSI of 47.23 indicates a balanced entry point for investors seeking stability and growth in the healthcare sector.
๐ Stock trades at $750.63 with 25.41% upside potential to $941.40 target.
๐ฐ Revenue grew 6.00% while generating $5.66 billion in free cash flow.
๐ Analysts rate 15 buys versus only 2 holds, showing strong bullish sentiment.
โ๏ธ RSI at 47.23 signals a balanced entry point, neither overbought nor oversold.
๐ McKesson trades at $750.63 with a market cap of $87.88 billion, offering analysts an average target price of $941.40 for roughly 25.41% upside potential.
๐ฐ The company reports impressive revenue growth of 6.00% and generates substantial free cash flow of $5.66 billion to support strategic initiatives.
๐ Analyst sentiment is strongly bullish with 15 buy ratings and only 2 hold ratings, indicating high confidence in the firm's execution.
๐ Technical indicators show the stock trading below its 50-day ($790.18) and 200-day ($824.19) moving averages, suggesting a short-term bearish trend.
โ๏ธ The Relative Strength Index (RSI) stands at 47.23, signaling that the stock is neither overbought nor oversold and presents a balanced entry point.
๐ฅ McKesson operates through key segments including North American Pharmaceutical and Oncology & Multispecialty, serving as a backbone for the US healthcare system.
๐ก Strategic initiatives in gene therapy and cancer care technology are enhancing the company's competitive moat and long-term growth prospects.
Bullish Signals
Target price $941.40 suggests 25.41% upside from $750.63.
Forward P/E of 14.91 indicates reasonable valuation.
Risk Factors
Trading below 50-day ($790.18) and 200-day ($824.19) moving averages.
Modest dividend yield of 0.44% with low payout ratio of 8.26%.
Bullish Signals
Analysts project an average target price of $941.40, suggesting approximately 25.41% upside from the current trading price of $750.63.
The company achieved impressive revenue growth of 6.00%, demonstrating expansion capabilities even in a challenging economic climate.
McKesson generated substantial free cash flow of $5.66 billion, providing financial flexibility for growth investments and shareholder returns.
Analyst sentiment is overwhelmingly positive with 15 buy ratings compared to only 2 hold ratings and zero sell ratings.
The forward P/E ratio of 14.91 indicates a reasonable valuation relative to projected earnings growth.
Risk Factors
The stock is currently trading below its 50-day moving average ($790.18) and 200-day moving average ($824.19), indicating a short-term bearish technical trend.
The dividend yield is modest at 0.44% with a low payout ratio of 8.26%, which may be less attractive for income-focused investors compared to peers.
McKesson Corporation (MCK) is identified as one of the three dominant wholesalers in the US drug distribution oligopoly, alongside Cardinal Health and Cencora. As of June 18, 2026, the stock traded near record levels at approximately $750.63 per share, reflecting a market capitalization of roughly $87.9 billion. The company is classified within the large-cap healthcare value and quality bucket, trading on an earnings multiple of about 19 times trailing earnings.
The business model relies on high volumes across pharmaceuticals and medical products to generate robust cash flows despite operating on thin margins, typically in the low single digits. McKesson's revenue is primarily derived from distributing branded and generic prescription drugs, over-the-counter medications, and medical-surgical supplies to pharmacies, hospitals, and healthcare providers. Additionally, the company leverages technology offerings and specialty distribution services for complex therapies like oncology to defend its margins against industry commoditization.
Long-term demand for McKesson is anchored by favorable demographic trends and rising prescription volumes. However, the sector faces structural risks from regulatory pressure on drug pricing and reimbursement rates. The article notes that while there was no fresh corporate news or specific earnings guidance released recently, the stock's positioning remains a key focus for investors evaluating the broader drug distribution sector.
๐ Trades near $750.63 with $87.9B market cap.
๐ Top three US drug distributor by revenue.
๐ฐ Trades at 19x trailing earnings with strong cash flow.
๐ Operates on thin single-digit operating margins.
โ ๏ธ Faces regulatory pressure on drug pricing and reimbursement.
๐ McKesson trades near record levels at $750.63 per share with a market capitalization of approximately $87.9 billion as of June 18, 2026.
๐ The company ranks among the top three US drug distributors by revenue, competing directly with Cardinal Health and Cencora in an oligopolistic market.
๐ฐ McKesson trades at roughly 19 times trailing earnings, placing it slightly above some competitors but supported by robust cash flow generation.
๐ The sector operates on thin low single-digit operating margins, relying on high volume and logistics efficiency to maintain profitability.
๐ Long-term growth is driven by demographic trends and increasing prescription volumes across branded and generic pharmaceuticals.
โ ๏ธ Structural risks include ongoing regulatory pressure on drug pricing and reimbursement rates which could impact future revenue streams.
๐ป The company diversifies its portfolio through technology offerings and specialty distribution services for complex therapies like oncology.
๐ McKesson is a constituent of the Standard & Poor's 500 index, reflecting its status as a major large-cap healthcare entity.
Bullish Signals
Trading near record levels showing strong investor confidence.
Robust cash flows from high-volume pharmaceutical operations.
Long-term demand supported by positive demographic trends.
Margins defended via technology and specialty services.
McKesson stock is trading near record levels, indicating strong market sentiment and investor confidence in the company's current valuation.
The company possesses robust cash flows generated from high-volume operations across pharmaceuticals and medical products.
Long-term demand fundamentals are supported by positive demographic trends and rising prescription volumes in the US healthcare sector.
McKesson successfully defends its margins through technology offerings and specialty distribution services for complex therapies.
Risk Factors
The drug distribution sector operates on thin operating margins, often limited to low single digits, which constrains overall profitability growth.
Regulatory pressure on drug pricing and reimbursement remains a significant structural risk that could negatively impact future revenue and margins.
The industry faces the challenge of commoditization, requiring continuous investment in technology and specialty services to maintain competitive positioning.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)